Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
91
resultados
Última actualización
13/09/2026 [07:01:00]
Resultados 25 a 50 de 91
Resumen de: US20260242448A1
The present disclosure provides a broad-spectrum bispecific antibody against novel coronaviruses, comprising a first targeting domain D1 targeting a first epitope of a SARS-CoV-2 RBD domain, and a second targeting domain D2 targeting a second epitope of the SARS-CoV-2 RBD domain. The bispecific antibody of the present disclosure has a broad-spectrum neutralizing activity and can effectively neutralize SARS-CoV-2 and various highly infectious and harmful SARS-CoV-2 variant strains, thus showing significant application value in the prevention, treatment, and/or detection of infections caused by novel coronaviruses.
Resumen de: AU2026210797A1
WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies 5 N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, and the designing of treatment targets and designing of vaccine targets. In the above amino acid sequence group, it is found that P272 in only one aa261-275 sequence of an S protein is a residue with a low-frequency mutation, and the remaining 19 sequences are 10 conservative amino acid sequences, do not contain the currently discovered virus mutation sites, and are highly conservative, which can effectively cope with the unfavorable situation of high-frequency mutation of SARS-CoV-2 at present. WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid 5 sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, a
Resumen de: US20260242763A1
0000 A fully human ACE2-Fc fusion protein, a pharmaceutical composition, preparation and kit containing same, and a nasal spray containing the fusion protein. Also provided is a use of the fusion protein for broad-spectrum prevention of coronavirus infections, such as infections with coronavirus SARS-CoV-2 and known and unknown variants thereof, including but not limited to original Hu-1, alpha, beta, gamma, delta, mu, omicron, JN.1, and/or other future strains. Also provided are a method for producing the fusion protein, and a method for using the fusion protein to prevent and/or treat infections with coronavirus SARS-CoV-2 and known and unknown variant strains thereof. Further provided is a use of the fusion protein and the pharmaceutical composition and preparation containing same for preventing the spread of coronavirus SARS-CoV-2 and known and unknown variant strains in infected subjects.
Resumen de: US20260242881A1
0000 Methods are provided for determining whether a subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, influenza A, human immunodeficiency virus type 1 (HIV-1), methicillin-susceptible Staphylococcus aureus (MSSA), or methicillin-resistant Staphylococcus aureus (MRSA), or has been exposed to an organophosphate (OP). Such methods include determining the measuring methylation status of numerous differentially methylated regions (DMRs) in the genomic DNA of particular PBMCs, such as those provided in Table 1, and in some examples also determining an amount of accessible chromatin in the isolated immune cells. Also provided are nucleic acid probes, arrays, solid supports (such a chip or nanosphere) and kits that can be used with such methods.
Resumen de: US20260240794A1
The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.
Resumen de: US20260240922A1
0000 The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, comprising a lactic acid bacterium. The chemosensory disorder can be a chemosensory disorder that occurs after SARS-CoV-2 viral infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect against a chemosensory disorder, and a pharmaceutical product or a food product that is safe for mammals including humans can be provided.
Resumen de: US20260242415A1
0000 The present invention relates to novel cyclic peptides. The peptides bind viral proteins, particularly a conserved site on the SARS-CoV-2 spike protein, and therefore the peptides can be useful for neutralizing SARS-CoV-2 variants. Accordingly, the invention also relates to medical use of the peptides.
Resumen de: WO2022117221A1
The present application relates to the use of a phthalazinedione in the prevention or treatment of sequelae of a SARS-CoV-2 infection. Pharmaceutical compositions, combinations, advantageous formulation techniques and a method of treatment are disclosed.
Resumen de: PL451191A1
Przedmiotem zgłoszenia jest liposomowy preparat, do stosowania w leczeniu COVID-19.
Resumen de: US20260234224A1
The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.
Resumen de: US20260235601A1
0000 The present invention relates to development of novel ssDNA aptamers comprising the oligonucleotide sequence that detect receptor-binding domain (RBD) of Severe Acute Respiratory Syndrome Corona virus (SARS-nCOV-2) infection. The ssDNA aptamers of the present invention may be used in lateral flow assays, electrochemical sensors and calorimetric sensors using gold nanoparticles. The present invention also relates to an analytical composition comprising said ssDNA aptamers. Further, the present invention also relates to a diagnostic kit for detecting RBD of SARS-nCoV-2.
Resumen de: US20260234196A1
Disclosed in the present invention are a polypeptide and a polypeptide composition specifically binding to a SARS-CoV-2 spike protein, and preparation methods and the uses thereof. By means of binding to S1 protein, the polypeptide and the polypeptide composition can block the binding of SARS-CoV-2 virus to a key target protein angiotensin-converting enzyme 2 (ACE2) protein on the surface of a host cell thereof, thereby providing a feasible targeting drug for the treatment of Coronavirus disease 2019.
Resumen de: US20260234629A1
0000 The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.
Resumen de: WO2026165666A1
The present disclosure provides a method for treating long CO VID ( e.g., severe long CO VID) or at least one symptom thereof in a subpopulation of subjects displaying a combination of biomarkers namely a blood level of secreted B-cell activating factor and of membrane BAFF in white blood cells higher than a corresponding reference level; and at least one of blood level of precursor- like marginal zone B-cell populations, zonulin, anti-Mi-2 nuclear antigen autoantibodies, anti-SmD autoantibodies, anti-Ul-snRNP-A autoantibodies, anti-RCN2 autoantibodies, lipopolysaccharide-binding protein (LBP), and p-D-glucan higher than a corresponding reference level, and APRIL lower than a corresponding reference level, comprising administering a therapeutically effective amount of a BAFF inhibitor to the subject. It also provides a method of diagnosing a subject as having long CO VID using the combination of biomarkers and a diagnosis kit comprising ligands for the biomarkers.
Resumen de: US20260234738A1
0000 The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
Resumen de: US20260232759A1
Anti-SARS-CoV-2 α/β-polypeptides, pharmaceutical compositions containing the same, and methods to inhibit, treat, and ameliorate SARS-CoV-2 infections in mammals, including humans.
Resumen de: US20260232725A1
0000 This invention provides a method for the therapeutic inhalation of hypochlorous acid (HOCl) to treat respiratory infections, reduce lung inflammation, and eliminate airborne pathogens in humans and animals. It describes controlled delivery of HOCl (10-50 ppm) via nebulizers, humidifiers, CPAP devices, ventilators, and direct tracheal instillation to improve oxygenation, break down mucus, and prevent secondary infections. The stabilized HOCl formulation ensures safety and efficacy, distinguishing it from surface disinfection applications. The method leverages HOCl's natural antimicrobial, anti-inflammatory, and mucolytic properties for direct respiratory treatment without toxicity or lung irritation. Applications include treating pneumonia, COVID-19, asthma, bronchitis, and ventilator-associated infections, as well as reducing airborne pathogen transmission in enclosed spaces. The invention presents a novel, non-toxic, and cost-effective approach to respiratory care, enhancing both individual treatment and public health disease mitigation.
Resumen de: US20260232749A1
A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt % total catechins, at least 20 wt % total chlorogenic acids, and optionally up to 30 wt % total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.
Resumen de: WO2026165610A1
The present invention relates to a pharmaceutical composition comprising the lipopeptide adjuvant Cys-Dipalmitoyl-Ser-Lys-Lys-Lys-Lys-PEG2-NH2 (otherwise referred to as dipalmitoyl- S-glyceryl-cysteine or Pam2Cys), an antigen, and mannitol, for the treatment and/or prevention of respiratory infections. Disclosed herein, is NoVCoV, a nasal dry powder vaccine that provides a novel and stable alternative to traditional liquid vaccines. This formulation is not only effective for preventing and/or treating COVID-19 but is also adaptable for addressing other respiratory infections.
Resumen de: WO2026169917A1
Provided are engineered SARS-CoV-2 virus-like particles (VLPs) and methods of making and using the VLPs for mRNA delivery. A 3 plasmid (3P) VLP system displays ~7-fold higher viral entry efficiency compared to VLPs formed by co-transfection with 4 plasmids. A 2 plasmid (2P) VLP system is provided where one vector carries the viral surface glycoprotein and the second carries the remaining SARS-CoV-2 structural proteins and reporter gene. The VLPs can carry up to four transgenes, including functional Cas9 mRNA for genome editing. Gene editing of specific target cell types is performed modifying VLP tropism. Successful mRNA delivery to mouse lungs shows that the SARS-CoV-2 VLPs can overcome natural biological barriers to enable pulmonary gene delivery.
Resumen de: US20260234220A1
0000 The present invention provides neutralizing monoclonal antibodies targeting the spike protein of Sarbecoviruses, such as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-1 or SARS-CoV-2 like COVID-19). The monoclonal antibodies of the invention can inhibit or neutralize SARS-CoV-1 or SARS-CoV-2 activity and advantageously be used for treating, preventing or diagnosing COVID-19 infection in humans due to their significant cross-reactivity among SARS-CoV-2 variants.
Resumen de: US20260234221A1
The disclosure relates to a pharmaceutical composition comprising human plasma-derived polyclonal, anti-SARS-CoV-2 hyperimmune globulins and to said pharmaceutical composition for use in the treatment of a SARS-CoV-2 Omicron variant infection. The disclosure also relates to a method for the preparation of a polyclonal, hyperimmune globulin composition anti-SARS-CoV-2.
Resumen de: EP4790065A1
Coronavirus spike protein variants for use in antigens for vaccines for coronavirus infection are provided.A coronavirus spike protein variant comprising:(a) a receptor binding domain (RBD) consisting of an amino acid sequence set forth in SEQ ID NO: 1;(b) an RBD consisting of an amino acid sequence obtained by substituting, deleting, inserting, or adding one to several amino acids in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of an RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1; or(c) an RBD consisting of an amino acid sequence that has at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of the RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1.
Resumen de: WO2025073771A1
The present invention inter alia relates to an use of an isolated polypeptide or an antigenic fragment thereof, comprising a polypeptide region having at least 60% sequence identity with any one of the polypeptide sequences selected from the group consisting of SEQ ID No.: 1-11, 16-20 and 23-28; wherein the isolated polypeptide is having a length of no more than 200 contiguous amino acids for diagnosing Long COVID or Post-Vac-Syndrome, or for predicting a risk of developing Long COVID or Post-Vac-Syndrome. The present invention also relates to the isolated polypeptide or antigenic fragment thereof for use in preventing, treating or ameliorating Long COVID or Post-Vac-Syndrome., as well as to a method of detecting a presence of antibodies against SARS-CoV-2 in a subject, comprising the step of contacting a sample of said subject with at least one of the polypeptide or antigenic fragment thereof.
Nº publicación: AU2026206109A1 06/08/2026
Solicitante:
GILEAD SCIENCES INC
Gilead Sciences, Inc.
Resumen de: AU2026206109A1
Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: , wherein the 1’ position of the nucleoside sugar is substituted. R¹ R¹¹¹ R¹ R³ X"" R² ul u l ¹ ²
BOPI
Sede Electrónica
